Terms: = Brain cancer AND FGFR3, CD333, 2261, ENSG00000068078, P22607, JTK4, ACH, HSFGFR3EX, CEK2 AND Treatment
33 results:
1. Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients.
Stepien N; Mayr L; Schmook MT; Raimann A; Dorfer C; Peyrl A; Azizi AA; Schramm K; Haberler C; Gojo J
Pediatr Blood Cancer; 2024 Mar; 71(3):e30836. PubMed ID: 38177074
[TBL] [Abstract] [Full Text] [Related]
2. Systematic review and cumulative analysis of clinical properties of BRAF V600E mutations in PLNTY histological samples.
Baumgartner ME; Lang SS; Tucker AM; Madsen PJ; Storm PB; Kennedy BC
Childs Nerv Syst; 2024 May; 40(5):1361-1366. PubMed ID: 38150037
[TBL] [Abstract] [Full Text] [Related]
3. Licochalcone A: A Potential Multitarget Drug for Alzheimer's Disease treatment.
Olloquequi J; Ettcheto M; Cano A; Fortuna A; Bicker J; Sánchez-Lopez E; Paz C; Ureña J; Verdaguer E; Auladell C; Camins A
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762479
[TBL] [Abstract] [Full Text] [Related]
4. Lung cancer presenting with central nervous system metastasis: Clinicopathological and molecular analysis of 171 cases.
Demleitner M; Erlenbach-Wünsch K; Coras R; Erber R; Polifka I; Eyüpoğlu I; Fuchs F; Hartmann A; Agaimy A
Ann Diagn Pathol; 2023 Apr; 63():152082. PubMed ID: 36634550
[TBL] [Abstract] [Full Text] [Related]
5. Identification of upregulated genes in glioblastoma and glioblastoma cancer stem cells using bioinformatics analysis.
Caglar HO; Duzgun Z
Gene; 2023 Jan; 848():146895. PubMed ID: 36122609
[TBL] [Abstract] [Full Text] [Related]
6. Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics.
Vagvala S; Guenette JP; Jaimes C; Huang RY
Cancer Imaging; 2022 Apr; 22(1):19. PubMed ID: 35436952
[TBL] [Abstract] [Full Text] [Related]
7. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Lassman AB; Sepúlveda-Sánchez JM; Cloughesy TF; Gil-Gil MJ; Puduvalli VK; Raizer JJ; De Vos FYF; Wen PY; Butowski NA; Clement PMJ; Groves MD; Belda-Iniesta C; Giglio P; Soifer HS; Rowsey S; Xu C; Avogadri F; Wei G; Moran S; Roth P
Clin Cancer Res; 2022 Jun; 28(11):2270-2277. PubMed ID: 35344029
[TBL] [Abstract] [Full Text] [Related]
8. Discovery of ASP5878: Synthesis and structure-activity relationships of pyrimidine derivatives as pan-FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity.
Kuriwaki I; Kameda M; Iikubo K; Hisamichi H; Kawamoto Y; Kikuchi S; Moritomo H; Terasaka T; Iwai Y; Noda A; Tomiyama H; Kikuchi A; Hirano M
Bioorg Med Chem; 2022 Apr; 59():116657. PubMed ID: 35219181
[TBL] [Abstract] [Full Text] [Related]
9. Targeting gene fusions in glioma.
Kim PL
Curr Opin Neurol; 2021 Dec; 34(6):840-847. PubMed ID: 34766555
[TBL] [Abstract] [Full Text] [Related]
10. Precise editing of fgfr3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma.
Wu Y; Jin W; Wang Q; Zhou J; Wang Y; Tan Y; Cui X; Tong F; Yang E; Wang J; Kang C
Mol Ther; 2021 Nov; 29(11):3305-3318. PubMed ID: 34274537
[TBL] [Abstract] [Full Text] [Related]
11. Targeting fibroblast growth factor receptors to combat aggressive ependymoma.
Lötsch D; Kirchhofer D; Englinger B; Jiang L; Okonechnikov K; Senfter D; Laemmerer A; Gabler L; Pirker C; Donson AM; Bannauer P; Korbel P; Jaunecker CN; Hübner JM; Mayr L; Madlener S; Schmook MT; Ricken G; Maaß K; Grusch M; Holzmann K; Grasl-Kraupp B; Spiegl-Kreinecker S; Hsu J; Dorfer C; Rössler K; Azizi AA; Foreman NK; Peyrl A; Haberler C; Czech T; Slavc I; Filbin MG; Pajtler KW; Kool M; Berger W; Gojo J
Acta Neuropathol; 2021 Aug; 142(2):339-360. PubMed ID: 34046693
[TBL] [Abstract] [Full Text] [Related]
12. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with fgfr3-TACC3 fusions.
Mata DA; Benhamida JK; Lin AL; Vanderbilt CM; Yang SR; Villafania LB; Ferguson DC; Jonsson P; Miller AM; Tabar V; Brennan CW; Moss NS; Sill M; Benayed R; Mellinghoff IK; Rosenblum MK; Arcila ME; Ladanyi M; Bale TA
Acta Neuropathol Commun; 2020 Nov; 8(1):186. PubMed ID: 33168106
[TBL] [Abstract] [Full Text] [Related]
13. Targeted Therapy with Anlotinib for a Patient with an Oncogenic fgfr3-TACC3 Fusion and Recurrent Glioblastoma.
Wang Y; Liang D; Chen J; Chen H; Fan R; Gao Y; Gao Y; Tao R; Zhang H
Oncologist; 2021 Mar; 26(3):173-177. PubMed ID: 32949176
[TBL] [Abstract] [Full Text] [Related]
14. Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility - a prospective, translational study.
Nørøxe DS; Yde CW; Østrup O; Michaelsen SR; Schmidt AY; Kinalis S; Torp MH; Skjøth-Rasmussen J; Brennum J; Hamerlik P; Poulsen HS; Nielsen FC; Lassen U
Mol Oncol; 2020 Nov; 14(11):2727-2743. PubMed ID: 32885540
[TBL] [Abstract] [Full Text] [Related]
15. Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment.
Pepe F; Pisapia P; Del Basso de Caro ML; Conticelli F; Malapelle U; Troncone G; Martinez JC
Histol Histopathol; 2020 Jul; 35(7):741-749. PubMed ID: 31872418
[TBL] [Abstract] [Full Text] [Related]
16. Acetylcholine Receptor Activation as a Modulator of Glioblastoma Invasion.
Thompson EG; Sontheimer H
Cells; 2019 Oct; 8(10):. PubMed ID: 31590360
[TBL] [Abstract] [Full Text] [Related]
17. Recurrent Papillary Glioneuronal Tumor.
Goethe EA; Youssef M; Patel AJ; Jalali A; Goodman JC; Mandel JJ
World Neurosurg; 2019 Aug; 128():127-130. PubMed ID: 31078809
[TBL] [Abstract] [Full Text] [Related]
18. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.
Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M
J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200
[TBL] [Abstract] [Full Text] [Related]
19. Role of Muscarinic Acetylcholine Receptors in Breast cancer: Design of Metronomic Chemotherapy.
Sales ME; Español AJ; Salem AR; Pulido PM; Sanchez Y; Sanchez F
Curr Clin Pharmacol; 2019; 14(2):91-100. PubMed ID: 30501602
[TBL] [Abstract] [Full Text] [Related]
20. The role of fibroblast growth factors and their receptors in gliomas: the mutations involved.
Georgiou V; Gkretsi V
Rev Neurosci; 2019 Jul; 30(5):543-554. PubMed ID: 30379640
[TBL] [Abstract] [Full Text] [Related]
[Next]
